全文获取类型
收费全文 | 7413篇 |
免费 | 696篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 411篇 |
妇产科学 | 113篇 |
基础医学 | 1047篇 |
口腔科学 | 167篇 |
临床医学 | 748篇 |
内科学 | 1234篇 |
皮肤病学 | 79篇 |
神经病学 | 571篇 |
特种医学 | 366篇 |
外科学 | 1190篇 |
综合类 | 257篇 |
一般理论 | 4篇 |
预防医学 | 774篇 |
眼科学 | 96篇 |
药学 | 444篇 |
中国医学 | 47篇 |
肿瘤学 | 537篇 |
出版年
2021年 | 112篇 |
2020年 | 78篇 |
2019年 | 125篇 |
2018年 | 129篇 |
2017年 | 110篇 |
2016年 | 94篇 |
2015年 | 127篇 |
2014年 | 180篇 |
2013年 | 247篇 |
2012年 | 328篇 |
2011年 | 355篇 |
2010年 | 225篇 |
2009年 | 206篇 |
2008年 | 282篇 |
2007年 | 281篇 |
2006年 | 313篇 |
2005年 | 280篇 |
2004年 | 309篇 |
2003年 | 277篇 |
2002年 | 266篇 |
2001年 | 216篇 |
2000年 | 228篇 |
1999年 | 201篇 |
1998年 | 120篇 |
1997年 | 118篇 |
1996年 | 95篇 |
1995年 | 106篇 |
1994年 | 96篇 |
1993年 | 87篇 |
1992年 | 173篇 |
1991年 | 161篇 |
1990年 | 129篇 |
1989年 | 148篇 |
1988年 | 171篇 |
1987年 | 149篇 |
1986年 | 160篇 |
1985年 | 129篇 |
1984年 | 81篇 |
1983年 | 94篇 |
1982年 | 70篇 |
1981年 | 52篇 |
1980年 | 70篇 |
1979年 | 72篇 |
1978年 | 64篇 |
1977年 | 55篇 |
1976年 | 54篇 |
1974年 | 59篇 |
1973年 | 66篇 |
1972年 | 61篇 |
1971年 | 60篇 |
排序方式: 共有8149条查询结果,搜索用时 31 毫秒
1.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献2.
Arthur L. Malkani Kevin J. Himschoot Kevin L. Ong Edmund C. Lau Doruk Baykal John R. Dimar Steven D. Glassman Daniel J. Berry 《The Journal of arthroplasty》2019,34(5):907-911
Background
Patients undergoing primary total hip arthroplasty (THA) following lumbar spine fusion have an increased incidence of dislocation compared to those without prior lumbar fusion. The purpose of this study is to determine if timing of THA prior to or after lumbar fusion would have an effect on dislocation and revision incidence in patients with both hip and lumbar spine pathology.Methods
One hundred percent Medicare inpatient claims data from 2005 to 2015 were used to compare dislocation and revision risks in patients with primary THA with pre-existing lumbar spine fusion vs THA with subsequent lumbar spine fusion within 1, 2, and 5 years after the index THA. A total of 42,300 patients met inclusion criteria, 28,668 patients of which underwent THA with pre-existing lumbar spinal fusion (LSF) and 13,632 patients who had prior THA and subsequent LSF. Patients who had THA first followed by LSF were further stratified based on the interval between index THA and subsequent LSF (1, 2, and 5 years), making 4 total groups for comparison. Multivariate cox regression analysis was performed adjusting for age, socioeconomic status, race, census region, gender, Charlson score, pre-existing conditions, discharge status, length of stay, and hospital characteristics.Results
Patients with prior LSF undergoing THA had a 106% increased risk of dislocation compared to those with LSF done 5 years after THA (P < .001). Risk of revision THA was greater in the pre-existing LSF group by 43%, 41%, and 49% at 1, 2, and 5 years post THA compared to the groups with THA done first with subsequent LSF. Dislocation was the most common etiology for revision THA in all groups, but significantly higher in the prior LSF group (26.6%).Conclusion
Results of this study demonstrate that sequence of surgical intervention for concomitant lumbar and hip pathology requiring LSF and THA respectively significantly impacts the fate of the THA performed. Patients with prior LSF undergoing THA are at significantly higher risk of dislocation and subsequent revision compared to those with THA first followed by delayed LSF.Level of Evidence
3. 相似文献3.
Doreen A. Ezeife MD Francois Dionne PhD Aline Fusco Fares MD Ellen Laura Rose Cusano MD Rouhi Fazelzad BSc MISt Wenzie Ng BSc MPharm RPh Don Husereau BSc Pharm MSc Farzad Ali BPharm MSc Christina Sit MSc Barry Stein B.Com BCL LLB Jennifer H. Law MSc Lisa Le MSc Peter Michael Ellis MD MMed PhD Scott Berry MD Stuart Peacock PhD Craig Mitton PhD Craig C. Earle MD Kelvin K. W. Chan MD PhD Natasha B. Leighl MD MMSc 《Cancer》2020,126(7):1530-1540
4.
目的建立保健食品原料评价体系(Functional Food Crude Materials Evaluation System,FUFMES),为保健食品原料目录排名提供科学依据与技术保障。方法首先,利用文献调研和多轮专家访谈方法筛选FUFMES的指标并确定其层级关系;第二,使用层次分析法(Analytic Hierarchy Process,AHP)计算指标权重,具体方法是依据专家打分构建判断矩阵,利用R语言进行一致性检验与最大特征根检验,得出各级指标权重;第三,使用极值法计算原料的单个指标值;第四,利用线性加权综合法得到每种原料的评价指数并据此进行排名;最后,将获得的分析结果与专家评价结果进行比较。结果 FUFMES包括6个一级指标、39个二级指标、11个三级指标。利用FUFMES对9种保健食品原料进行评价,获得的评价指数依次是:西洋参(0.49)、人参(0.48)、银杏叶(0.21)、灵芝孢子粉(0.08)、鱼油(0.06)、螺旋藻(0.03)、辅酶Q10(0.02)、褪黑素(0.01)、大蒜油(-0.03)。基于该评价指数的排名结果与专家评价结果显示了较高一致性。结论构建了科学、完整的FUFMES,FUFMES将成为保健食品原料目录评价与排名的有力工具,为推进保健食品原料备案制提供科学依据与技术保障。 相似文献
5.
Cody C. Wyles Joseph A. Panos Matthew T. Houdek Robert T. Trousdale Daniel J. Berry Michael J. Taunton 《The Journal of arthroplasty》2019,34(3):517-521
Background
Spondyloepiphyseal dysplasia (SED) is rare genetic condition which leads to skeletal and joint deformities that can predispose patients to degenerative joint disease. There are limited reports on the results of total hip arthroplasty (THA) in this patient population. The purpose of this study is to review clinical and radiographic outcomes of THA performed in patients with SED at one institution.Methods
Among 43,917 patients undergoing primary THA from 1970 to 2015, we identified 50 THAs performed in 29 patients with SED; 21 patients underwent bilateral THA (none simultaneous). There were 16 females and 13 males; mean age, body mass index, and height were 39 years, 28.7 kg/m2, and 145 cm, respectively. All patients were able to ambulate prior to the THA. Mean follow-up was 11 years (range 2-38).Results
Mean implant survival for primary THA in SED patients at the 5, 10, and 20-year time points was 96%, 85%, and 55%, respectively. Thirteen patients required revision THA, most commonly for polyethylene wear (n = 6) and aseptic loosening (n = 5), and 4 additional patients underwent nonrevision reoperations. Prior to surgery, 90% of patients had severe or moderate pain, which was reduced to 8% of patients postoperatively (P < .001). Mean Harris Hip Score improved from 47 to 87 (P < .001). Prior to surgery, 64% of patients required gait aids, which reduced to 34% postoperatively (P < .001).Conclusion
THA provided significant pain reduction and improvement in function, with a majority of patients ambulating independently following the procedure. There was a high incidence of complications following THA in patients with SED, most commonly secondary to polyethylene wear and osteolysis from conventional polyethylene and historical implants.Level of Evidence
Level IV, Therapy. 相似文献6.
7.
目的:促进老年人新型冠状病毒肺炎中药防治的安全性及合理性。方法:根据全国各省制定的新型冠状病毒肺炎中医药预防方案,结合老年人的生理特质、病理情况、基础疾病及用药特点进行分析。结果:提出老年人新型冠状病毒肺炎中药防治的合理用药策略。结论:老年人作为预防新冠病毒感染的重点人群,应加强合理用药干预,确保中药用药安全有效。 相似文献
8.
9.
Raghav Govindarajan MD James D. Berry MD Sabrina Paganoni MD PhD Michael T. Pulley MD PhD Zachary Simmons MD 《Muscle & nerve》2020,62(3):321-326
Amyotrophic lateral sclerosis (ALS) has the largest drug pipeline among neuromuscular diseases, with over 160 companies actively involved in ALS research. There is a growing need to recruit trial participants, but ALS patients often have limited mobility and most ALS trials are conducted in a small number of major centers. These factors effectively limit patient participation, particularly for those in rural areas. The current coronavirus disease 2019 (COVID-19) pandemic has necessitated the more widespread use of telemedicine technology for clinical care, and has prompted consideration of its increased use for clinical trials. In this opinion piece, we describe the current state of telemedicine for recruitment, consenting, and screening of participants for clinical trials. We also summarize the available data on remote administration of outcome measures. Current challenges include validation of outcome measures for remote assessment, as well as technological, regulatory, and licensure barriers. 相似文献